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Abstract
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) recep-
tors are highly overexpressed in benign insulinomas,
permitting in vivo tumour visualisation with GLP-1
receptor scanning. The present study sought to evaluate
the GLP-1 receptor status in vitro in other pancreatic
disorders leading to hyperinsulinaemic hypoglycaemia,
specifically after gastric bypass surgery.
Methods Fresh frozen pancreatic tissue samples (n=7)
from six gastric bypass surgery patients suffering from
hyperinsulinaemic hypoglycaemia were evaluated for
GLP-1 receptor content using in vitro receptor autoradi-
ography, and compared with normal pancreas and with
pancreatic insulinoma tissues.
Results GLP-1 receptor analysis of the pancreatic tis-
sues, which histopathologically were compatible with
nesidioblastosis and originated from post-bypass hypogly-
caemic patients, revealed a mean density value of GLP-1
receptors in the islets of 1,483±183 dpm/mg tissue.
Pharmacological characterisation indicated the presence of
specific GLP-1 receptors. The density of islet GLP-1
receptor in post-gastric bypass patients did not differ from
that of normal pancreas (1,563±104 dpm/mg tissue, n=10).
Receptor density in pancreatic acini was low in post-bypass
and control conditions. In contrast, benign insulinomas
showed a high density of GLP-1 receptors, with a mean
value of 8,302±1,073 dpm/mg tissue (n=6).
Conclusions/interpretation In contrast to insulinoma, hyper-
insulinaemic hypoglycaemia after gastric bypass surgery is
not accompanied by overexpression of GLP-1 receptor in
individual islets. Thus, patients with post-gastric bypass
hyperinsulinaemic hypoglycaemia are not candidates for
GLP-1 receptor imaging in vivo using radiolabelled exendin.
These GLP-1 receptor data support the notion that the islet
pathobiology of post-gastric bypass hypoglycaemia is
distinctly different from that of benign insulinomas.
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Introduction
Glucagon-like peptide-1 (GLP-1) is an important glucose-
dependent insulin secretagogue released primarily from the
small intestine in response to nutrient intake [1]. GLP-1
effects are mediated by GLP-1 receptors, which have been
identified as class 2 G-protein-coupled receptors and are
produced in particular in pancreatic islets, intestine, lung
and brain [1]. Recently, GLP-1 receptors have been found
to be overexpressed at very high density in virtually all
tested benign pancreatic insulinomas [2]. Compared with
tumours from other organs, insulinomas express by far the
highest level of GLP-1 receptors [3]. Based on these
observations, a diagnostic method was developed, which
permits localisation of benign insulinomas with a scanning
method using intravenously injected 111In-labelled DOTA-
exendin-4, a synthetic GLP-1 analogue [4]. The method
successfully localises benign insulinomas that remain
undetected with established diagnostic methods [5].
The magnitude of GLP-1 receptor production is largely
unknown in other pancreatic pathologies linked to excessive
insulin secretion. Preliminary in vitro and in vivo data in
malignant insulinomas indicate that only a subgroup of
tumours express GLP-1 receptors, while the remaining
tumours, including primary and metastasis, do not [6].
Another distinct clinical syndrome is that of postprandial
hypoglycaemia, typically occurring several years after gastric
bypass surgery for obesity [7–10]. In a small subset of
individuals, this form of hypoglycaemia is severe and
unresponsive to nutritional and medical management, and
partial pancreatectomy has been performed for symptom
control [7, 9, 10]. While the specific pathogenic mediators of
this syndrome remain unclear, food intake in patients with
this syndrome results in rapid elevations of plasma glucose,
insulin and C-peptide, with subsequent development of
hypoglycaemia during the later postprandial period [8]. It
remains unclear whether increased insulin secretion in this
syndrome is due to: (1) observed increases in secretion of
GLP-1, gastric inhibitory polypeptide or other incretins; (2)
altered responsiveness to incretins or other insulin secreta-
gogues; or (3) cell-autonomous insulin secretion [7]. In some
individuals with this syndrome, diffuse islet cell hyperplasia
and expansion of beta cell mass has been observed [9, 10]; in
other studies, increased nuclear size relative to body mass, but
not hyperplasia has been reported [7]. We hypothesised that
GLP-1 receptor production might be increased in pancreases
of patients with post-gastric bypass hypoglycaemia, potential-
ly contributing to their enhanced GLP-1 sensitivity and action.
In addition, we wished to determine whether GLP-1 receptor
levels might permit future GLP-1 receptor-mediated scanning
for evaluation of islet mass in this setting.
Thus, in vitro GLP-1 receptor autoradiography, a morpho-
logical method that can distinguish the pancreatic cell
populations, was used to quantify the GLP-1 receptor content
in islet cells and acini. GLP-1 receptor content in post-gastric
bypass hypoglycaemia patient samples was compared with
pancreas samples obtained from organ donors or from
patients undergoing pancreas surgery for benign or malignant
tumours, and with insulinoma tumour samples, a reference
tissue with extreme GLP-1 receptor overexpression [2].
Methods
Fresh frozen samples of pancreatic tissues were obtained
from surgically resected specimens. Of these samples, seven
were from six patients suffering from hyperinsulinaemic
hypoglycaemia after gastric bypass surgery and four were
normal pancreatic samples obtained at the time of pancreatic
surgery for benign or malignant non-endocrine tumours from
normoglycaemic patients. Samples were obtained from the
Joslin Diabetes Center and Beth Israel Deaconess Medical
Center. In addition, six normal pancreatic samples from organ
donors or tumour patients and six insulinoma samples were
collected at the Institute of Pathology, University of Berne for
use as controls. Informed consent was obtained from all
patients. The study conformed to the ethical guidelines of the
Joslin Diabetes Center, Beth Israel Deaconess Medical
Center and the Institute of Pathology, University of Bern,
and was carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2000.
In vitro GLP-1 receptor autoradiography was performed
as described previously [2], using 125I-labelled GLP-1(7–
36)amide (74 TBq/mmol [2,000 Ci/mmol]; Anawa, Wangen,
Switzerland) as radioligand. Competition experiments were
performed by adding increasing concentrations of the GLP-1
receptor-selective analogue GLP-1(7–36)amide, the GLP-2
receptor-selective analogue GLP-2 (Bachem, Bubendorf,
Switzerland) or the glucagon receptor-selective analogue
glucagon(1–29) (Bachem). Receptor density in islets and in
acini was quantitatively assessed using tissue standards
and a computer-assisted image processing system (Analysis
Imaging System; InterFocus, Mering, Germany). As a
positive control, human insulinomas were used in each
procedure [2].
Cryostat sections adjacent to those used for in vitro receptor
autoradiography were selected for insulin and synaptophysin
immunohistochemistry, in order to identify unambiguously all
pancreatic islets, as previously reported [11].
Results
GLP-1 receptors, assessed by in vitro receptor autoradiog-
raphy, were present in pancreatic islets and acini of all
patient samples examined, with levels in islets about two-
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to threefold higher than in acini, although substantial
individual variability in receptor density was observed. In
patients with post-gastric bypass hypoglycaemia syndrome,
the mean density of GLP-1 receptors was 1,483±
183 dpm/mg in islets and 529±107 in acinar tissue,
these values being similar to those of controls (Table 1).
Figure 1a–c shows representative images of a control
pancreas, a pancreas from a patient with post-gastric
bypass hypoglycaemia and an insulinoma. Upon histopa-
thology, post-gastric bypass hypoglycaemia syndrome
samples were characterised by a statistically significantly
increased islet size compared with the islets of control
patients (Table 1). The number of islets per surface area
was higher in bypass patients than in controls but did not
reach statistical significance (Table 1). Islets from post-
gastric bypass hypoglycaemic patients expressed moderate
GLP-1 receptor levels (Fig. 1b), while acini were only
weakly labelled. Pancreatic islets from controls had
similar moderate GLP-1 receptor levels while acini from
controls had low receptor levels. In contrast, benign
insulinoma tissue had homogeneous and very high levels
of GLP-1 receptors, as previously described [2].
To establish whether the receptors detected in post-
gastric bypass hypoglycaemic patients were specific
GLP-1 receptors, pharmacological characterisation was
performed in all tissues from this patient group and is
illustrated (Fig. 1d) in a competition experiment with one
of the patients. GLP-1 receptors in post-gastric bypass
patients were found to be of high affinity for GLP-1, with
cold GLP-1 displacing radiolabelled GLP-1 at low nano-
molar concentrations (Fig. 1d). The receptors were
specific for GLP-1, as only the GLP-1 analogue was able
to displace the radioligand with high affinity, whereas the
GLP-2 analogue or glucagon(1-29) bound only with low
Table 1 Subject characteristics, surgical procedure and pancreatic sample characterisation in post-gastric bypass patients with severe
hypoglycaemia requiring partial pancreatectomy, compared with controls
Sample
number
Demographic BMI (kg/m2) Clinical Histopathology GLP-1 receptor
density (dpm/mg)
Age
(years)
Sex Pre-GB Post-GB Glucosea Time to
pancreatectomyb
Islet sizec Islet
numberd
Islete Acinare
Patients
1 28 F 46.8 26.2 2.3 1.8 0.021±0.012 2.8 1,202±222 570±114
2f 0.024±0.016 2.4 1,134±211 245±61
3 31 F 40.0 26.1 1.9 3.2 0.018±0.010 4.5 2,396±331 1,001±93
4 49 F 43.5 29.7 2.2 3.0 0.016±0.010 3.1 1,002±124 309±73
5 69 F 48.4 34.0 3.2 3 0.027±0.016 7.6 1,539±144 784±89
6 46 M 40.6 23.1 2.4 1.8 0.026±0.018 2.3 1,295±182 280±90
7 41 F 41.3 25.1 2.9 3.8 0.013±0.007 1.5 1,814±127 511±35
Meang 0.021±0.002 3.46±2.05 1,483±183 529±107
Controls
A 0.011±0.002h 1.98±0.78i 1,563±104 676±101
B 8,302±1,073j
All patients underwent Roux-en-Y gastric bypass (GB).
Control A represents normal pancreas (gender M/F: 5/5; mean age: 48±6 years; n=10). Control B represents benign insulinomas (sex M/F: 2/4;
mean age: 50±5 years; n=6)
a Postprandial in mmol/l
b Time (in years) from bypass to pancreatectomy
c Islet size in mm2 , mean ± SD, was quantified for the 50 largest islets in each sample according to Service et al. [9]
d Islet number was quantified in the whole sample area and expressed as islet number per mm2 (islet size ≥0.002 mm2 )
eMean ± SEM
f Samples 1 and 2 are two separate samples from the same patient
g Of post-bypass patients
hMean ± SEM (n=10); control values were significantly different (p<0.005, unpaired t test) from the bypass patient values (0.021±0.002 mm2 ;
mean ± SEM, n=7).
i Mean ± SD (n=10); lower but not significantly different (p>0.05, unpaired t test) from the mean ± SD (n=7) of islet numbers in bypass patients
(3.46±2.05 islets per mm2 )
j In tumour tissue
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affinity. This rank order of potency of the various
analogues is characteristic of and specific to the GLP-1
receptor.
Discussion
Roux-en-Y gastric bypass is highly successful in reducing
body weight, improving metabolic status and normalising
hyperglycaemia in patients with type 2 diabetes [12]. One
increasingly recognised, albeit uncommon long-term com-
plication of this surgery is hyperinsulinaemic hypoglycae-
mia. In a very small subset of patients, hypoglycaemia may
be very severe and unresponsive to medical and nutritional
management; in some cases, partial pancreatectomy has
been performed for patient safety [10]. Pancreases from
these patients demonstrate islet cell hyperplasia, with
enlarged and/or more numerous islets, some of them
adjacent to and budding from ducts, consistent with so-
called nesidioblastosis [10]. Metabolic studies have demon-
strated dysregulation of insulin secretion following oral
liquid meals, potentially linked to increased incretin secretion
resulting from early nutrient exposure to the intestinal Roux
limb [8]. Increased incretin sensitivity could also contribute
to the syndrome. Furthermore, insulinoma has also been
reported in some individuals following gastric bypass
surgery. An important, but unanswered question is whether
there are any molecular parallels between insulinoma and
the excessive insulin secretion and potential islet cell
hyperplasia observed in this subgroup of post-gastric bypass
patients.
GLP-1 receptors mediate GLP-1 effects to stimulate
insulin secretion [1]. In gastric bypass patients, GLP-1
levels are increased in response to standard liquid meals [8],
suggesting a potential role for GLP-1 in mediating insulin
secretion and, potentially, islet expansion and/or protection
against apoptosis. It was previously unknown whether
differences in GLP-1 receptor levels could make an
additional contribution to the pathophysiology. Our studies
demonstrate that GLP-1 receptor content does not differ in
Post-gastric bypass
Neuroglycopenia
Pancreas
Insulinoma
Control Post-bypass Insulinoma
Control InsulinomaPost-bypass
a
c
b
d
Pancreas
–11
–10 –9 –8 –7 –6
0
50
100
12
5 I-
la
be
lle
d 
G
LP
-1
-s
pe
cif
ic 
bi
nd
in
g 
(%
)
log[compound] (mol/l)
Fig. 1 In vitro receptor autoradiography detection of GLP-1 receptor
in pancreatic samples from adult nesidioblastosis compared with
normal pancreas and insulinoma. a Insulin immunohistochemistry on
cryostat sections of control and post-bypass pancreas. Arrowheads,
islets surrounded by acini. Scale bars, 0.1 mm. Insulin immunohisto-
chemistry was also done on paraffin sections of insulinoma tissue.
Scale bar, 1 mm. b Autoradiograms showing total binding of 125I-
labelled GLP-1(7-36)amide, with moderate binding (arrowheads)
observed in islets from control and post-bypass samples, and weak
binding in acini. Very strong binding was observed in insulinoma
tissue. c Autoradiograms showing non-specific binding of 125I-
labelled GLP-1(7-36)amide in the presence of 100 nmol/l unlabelled
(cold) GLP-1(7-36)amide. d Competition experiment in pancreatic
islet tissue originating from post-bypass patients and showing high-
affinity displacement of 125I-labelled GLP-1(7-36)amide by GLP-1
receptor-selective agonist GLP-1(7-36)amide (circles), and low-
affinity displacement by GLP-2 receptor-selective agonist GLP-2
(triangles) and glucagon receptor-selective agonist glucagon(1-29)
(squares). Values are mean ± SEM; n=3
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islet or acinar tissue in the post-gastric bypass hypoglycae-
mia setting. Moreover, the normal content of GLP-1
receptors is in sharp contrast to the robust overexpression
of GLP-1 receptors in human insulinoma. Our data thus
suggest that different pathophysiological mechanisms con-
tribute to increased insulin secretion in these two hyper-
insulinaemic hypoglycaemic conditions.
Our results are based on in vitro receptor autoradiogra-
phy, a method that has a number of advantages [2, 3]. First,
morphology permits distinction of islets from acini, which
is important as both compartments normally express GLP-1
receptors. Second, autoradiography is quantitative and, in
contrast to immunohistochemistry, permits precise evalua-
tion of GLP-1 receptor density in specific compartments
[3]. Third, it is a highly specific method that allows
assessment of ligand binding through direct pharmacolog-
ical characterisation of the binding sites.
What, if any, immediate clinical consequences could
result from the present study? We had previously considered
the possible use of 111In-labelled DOTA-exendin-4 for in
vivo imaging of post-gastric bypass hypoglycaemia patients,
with a view to ruling out insulinoma and assessing possible
increases in islet mass. Our results do not support the
rationale behind such an approach at the present time, as
neither islet nor acinar GLP-1 receptor levels differed in
post-gastric bypass patients with hypoglycaemia compared
with control pancreas.
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